Abstract: SA-PO1082
Use of an LCP Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Session Information
- Transplantation: Clinical - II
November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2102 Transplantation: Clinical
Authors
- Wiseman, Alexander C., Porter Adventist Hospital, Denver, Colorado, United States
- Bunnapradist, Suphamai, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
- Alhamad, Tarek, Washington University in St Louis, St Louis, Missouri, United States
- Alloway, Rita R., University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
- Concepcion, Beatrice P., University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States
- Cooper, Matthew, Froedtert Hospital, Milwaukee, Wisconsin, United States
- Formica, Richard Nicholas, Yale School of Medicine, New Haven, Connecticut, United States
- Klein, Christina L., Piedmont Healthcare Inc, Atlanta, Georgia, United States
- Kumar, Vineeta, UAB Hospital, Birmingham, Alabama, United States
- Leca, Nicolae, University of Washington, Seattle, Washington, United States
- Shihab, Fuad S., The University of Utah School of Medicine, Salt Lake City, Utah, United States
- Taber, David J., Medical University of South Carolina, Charleston, South Carolina, United States
- Mulnick, Sarah, Evidera Inc, Bethesda, Maryland, United States
- Bushnell, Donald M., Evidera Inc, Bethesda, Maryland, United States
- Hadi, Monica, Evidera Inc, Bethesda, Maryland, United States
Background
LCPT (Envarsus XR®) is a common once-daily, extended-release oral tacrolimus formulation used in kidney transplantation. Variations in real-world use mean uncertainty remains on how best to use LCPT in kidney transplantation in de novo and conversion populations. The objective of this study was to address the gaps in published data by developing consensus statements on the use of LCPT in kidney transplantation using the Delphi process with a panel of expert clinicians.
Methods
A panel of 12 clinicians with expertise in nephrology and kidney transplantation reviewed available clinical evidence on LCPT. The Delphi panel survey consisted of three rounds of an online survey. Consensus was achieved when ≥75% agreed strongly or with reservation to a statement.
Results
Twenty-three statements were evaluated: 14 on de novo and nine on general or conversion use. After two rounds, consensus was achieved for 20 statements (Figure 1). De novo, LCPT was recognized as a first-line option based on its safety and efficacy compared to immediate-release tacrolimus. In a conversion setting, full consensus was achieved for converting to LCPT to address neurological side effects related to immediate-release tacrolimus and for the time required (~7 days) for steady state LCPT trough levels to be reached.
Conclusion
The consensus statements generated in this study provide a real-world guide to using LCPT in kidney transplantation, especially in a de novo setting, for which guidance is currently lacking.
Funding
- Commercial Support – Veloxis, Inc.